Support a fantastic team through providing functional leadership in the areas of business development, manufacturing, program planning and business strategy for Nobias. Spearhead program and platform partnering, provide executive leadership to Ph 2 development program, and work closely with the CEO on investor engagement and board management.

Provide hands-on support and functional leadership in the areas of business strategy and planning, corporate and business development, executive and business operations, and project and program management.

Biotech advisory practice supporting early-stage therapeutic companies by providing hands-on support and functional leadership in the areas of:- Business strategy and planning- Corporate and business development- Executive and business operations- Project and program management

Role supporting the SVP, R&D Pipeline and functioning as a chief of staff with primary responsibilities related to: • enabling delivery and shaping pipeline strategy across the following Therapeutic Area Units: Alternative Discovery & Development, Metabolic Pathways & Cardiovascular, Neuroscience, Rare Disease and Respiratory• ensuring effective anticipation of future needs across pharmaceutical R&D discovery• identifying and implementing key strategic efforts• supporting internal and external engagement, as well as capability development

Multi-year, multi-hundred million GBP programme transforming where and how our global R&D organisation works. Played key role in shaping the strategy and served as R&D Global Business Lead for the first 3 years of its implementation.

Formalised and led the centralised program management function ( team of 12) for the GSK R&D organization (c.10,000 staff, c.£3b annual budget).Served as secretariat to the R&D Operations Executive (executive sub-team of the R&D Leadership Team).

Led implementation of a global CoE strategy (framework to support better, more disciplined and efficient BD decision-making) for worldwide business development (WWBD) at GSK.• Named member of the WWBD Leadership Team in Jan 2011 and the Business Development Leaders Community in April 2011

Senior member of the internal business consulting group for the R&D Executive Team (RADEX), responsible for the formulation, articulation, and coordination of the R&D strategy and associated change initiativesWork included:• Filling key roles in project mgmt office for largest restructuring of GSK R&D since 2000 GW-SKB merger (£250M p.a. savings)• Project managing the handover of an integrated research site employing ~500 in Verona, Italy to a multinational CRO

• Management and Leadership - Managed (in consultant or manager capacity) 30 engagements, primarily in the life science and private equity practices - Directed activities of multiple parallel teams of up to 10 members, frequently across multiple international offices - Served as advisor to senior management of clients, often leading discussions of findings to CEOs, investors, and boards• Strategic Planning (selection) - Formulated corporate strategy for top 5 U.S. biotech company; strategy currently being implemented - Identified and assessed opportunities for indication expansion of an orphan drug with >$70M in first-year sales• Business Development (selection) - Evaluated the market for a new cancer vaccine; analysis led to a license agreement worth $260M for the client - Assessed acquisition opportunities in a new therapeutic area for a $10B multinational specialty pharmaceuticals company• Due Diligence (selection) - Evaluated the transplant diagnostics market for a $2B tools company; $130M acquisition completed 1/2009 - Led international team in modeling EU revenues of a CNS therapeutic for monetization; deal completed 4/2008

• Evaluated the pharmaceutical market in six therapeutic areas and proposed candidates for in-licensing or generic development

• Evaluated two new therapeutic areas and three companies as acquisition candidates• Assisted negotiation of co-promotion agreement with an international partner for the US market

• Led negotiation of license, option, and sponsored research agreements, evaluated over 85 technologies, and supported establishment of several newcos